Wilms tumor 1 gene, CD97, and the emerging biogenetic profile of glioblastoma

Neurosurgical Focus

Volumn 37, Issue 6, 2014, Pages

  Somasundaram, Aravind ^a   Ardanowski, Nathan ^a   Opalak, Charles F ^a   Fillmore, Helen L ^b   Chidambaram, Archana ^c   Broaddus, William C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

CD97; Glioblastoma; Wilms tumor 1 gene

Indexed keywords

CD97 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

BRAIN TUMOR; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; NEPHROBLASTOMA;

ANTIGENS, CD; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; WILMS TUMOR;

EID: 84916926100     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2014.9.FOCUS14506     Document Type: Article

References (34)

1. Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND, Bard JB: The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech Dev 40:85-97, 1993
2. Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, Lotz O, et al: CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57:1798-1806, 1997
3. Chen MY, Clark AJ, Chan DC, Ware JL, Holt SE, Chidambaram A, et al: Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression. J Neurooncol 103:87-102, 2011
4. Chiba Y, Hashimoto N, Tsuboi A, Rabo C, Oka Y, Kinoshita M, et al: Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. Brain Tumor Pathol 27:29-34, 2010
5. Chidambaram A, Fillmore HL, Van Meter TE, Dumur CI, Broaddus WC: Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness. Laboratory investigation. J Neurosurg 116:843-853, 2012
6. Clark AJ, Chan DC, Chen MY, Fillmore H, Dos Santos WG, Van Meter TE, et al: Down-regulation of Wilms' tumor 1 expression in glioblastoma cells increases radiosensitivity independently of p53. J Neurooncol 83:163-172, 2007
7. Clark AJ, Dos Santos WG, McCready J, Chen MY, Van Meter TE, Ware JL, et al: Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. J Neurosurg 107:586-592, 2007
8. Clark AJ, Ware JL, Chen MY, Graf MR, Van Meter TE, Dos Santos WG, et al: Effect of WT1 gene silencing on the tumorigenicity of human glioblastoma multiforme cells. Laboratory investigation. J Neurosurg 112:18-25, 2010
9. Dennis SL, Manji SS, Carrington DP, Scarcella DL, Ashley DM, Smith PJ, et al: Expression and mutation analysis of the Wilms' tumor 1 gene in human neural tumors. Int J Cancer 97:713-715, 2002
10. Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, et al: An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 61:1257-1269, 1990
11. Hamann J, Stortelers C, Kiss-Toth E, Vogel B, Eichler W, van Lier RA: Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol 28:1701-1707, 1998
12. Hashiba T, Izumoto S, Kagawa N, Suzuki T, Hashimoto N, Maruno M, et al: Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med Chir (Tokyo) 47:165-170, 2007
13. Hashimoto N, Tsuboi A, Chiba Y, Izumoto S, Oka Y, Yoshimine T, et al: [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors.] Brain Nerve 61:805-814, 2009 (Jpn)
14. Hohenstein P, Hastie ND: The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15:R196-R201, 2006
15. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, et al: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:963-971, 2008
16. Jin DI, Lee SW, Han ME, Kim HJ, Seo SA, Hur GY, et al: Expression and roles of Wilms' tumor 1-associating protein in glioblastoma. Cancer Sci 103:2102-2109, 2012
17. Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A, et al: Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 97:259-270, 2006
18. Kijima N, Hosen N, Kagawa N, Hashimoto N, Kinoshita M, Oji Y, et al: Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis. Anticancer Res 34:61-67, 2014
19. Little NA, Hastie ND, Davies RC: Identification of WTAP, a novel Wilms' tumour 1-associating protein. Hum Mol Genet 9:2231-2239, 2000
20. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA: The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 9:2143-2156, 1995
21. Menssen HD, Bertelmann E, Bartelt S, Schmidt RA, Pecher G, Schramm K, et al: Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens. J Cancer Res Clin Oncol 126:226-232, 2000
22. Mikesch JH, Schier K, Roetger A, Simon R, Buerger H, Brandt B: The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol 28:223-232, 2006
23. Nakahara Y, Okamoto H, Mineta T, Tabuchi K: Expression of the Wilms' tumor gene product WT1 in glioblastomas and medulloblastomas. Brain Tumor Pathol 21:113-116, 2004
24. Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, et al: Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors. Cancer Sci 95:822-827, 2004
25. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101:13885-13890, 2004
26. Omuro A, DeAngelis LM: Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842-1850, 2013
27. Rauscher J, Beschorner R, Gierke M, Bisdas S, Braun C, Ebner FH, et al: WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma. J Clin Pathol 67:556-561, 2014
28. Roberts SG: Transcriptional regulation by WT1 in development. Curr Opin Genet Dev 15:542-547, 2005
29. Safaee M, Clark AJ, Ivan ME, Oh MC, Bloch O, Sun MZ, et al: CD97 is a multifunctional leukocyte receptor with distinct roles in human cancers (review). Int J Oncol 43:1343-1350, 2013
30. Safaee M, Clark AJ, Oh MC, Ivan ME, Bloch O, Kaur G, et al: Overexpression of CD97 confers an invasive phenotype in glioblastoma cells and is associated with decreased survival of glioblastoma patients. PLoS ONE 8:e62765, 2013
31. Sitaram RT, Degerman S, Ljungberg B, Andersson E, Oji Y, Sugiyama H, et al: Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br J Cancer 103:1255-1262, 2010
32. Steinert M, Wobus M, Boltze C, Schütz A, Wahlbuhl M, Hamann J, et al: Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol 161:1657-1667, 2002
33. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
34. Tatsumi N, Oji Y, Tsuji N, Tsuda A, Higashio M, Aoyagi S, et al: Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol 32:701-711, 2008